Gadoversetamide indicated for intravenous use: 

• In patients with an abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues.
• To provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography.

MRI Contrast

• Bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) 
• Follow injection with a 5 mL normal saline flush. 
• Complete imaging procedure within 1 hour of injection.

Most common adverse reactions (incidence >2%) are: headache, vasodilatation, taste perversion, dizziness, nausea and paresthesia.

Headache

Taste disturbances

Dizziness

Paresthesia

• Nephrogenic Systemic Fibrosis (NSF) has occurred in patients with impaired elimination of Gadolinium Based Contrast Agents (GBCAs). Higher than recommended dosing or repeat dosing appears to increase the risk.
• Acute Kidney Injury (AKI) has occurred in patients with preexisting renal insufficiency. Use the lowest necessary dose of Gadoversetamide in these patients.
• Hypersensitivity reactions including fatal reactions have occurred, particularly in patients with history of allergy, drug reactions, or other hypersensitivity like disorders. Monitor these patients closely during and after administration of Gadoversetamide.
• Interference with laboratory measurements of serum iron, copper and zinc and in the measurement of serum calcium using the ortho-cresophthalin complexone (OCP) colorimetric method has occurred.